Silo Pharma, Inc. Common Stock SILO

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

SILO hizo una agrupación de acciones (split inverso) de 1:15 el 3 de junio de 2026: cada 15 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 6 ago

  Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

  Silo Pharma's subsidiary QwikAgents has partnered with Caylent, an AWS Premier Tier Services Partner, to build a new AWS-native platform. The collaboration aims to enhance scalability, performance, and security for enterprise deployment, with expected funding support from AWS and Caylent to accelerate commercialization and product innovation.

  

• GlobeNewswire Inc. 21 jul

  Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

  Silo Pharma announced progress on two strategic fronts: its QwikAgents AI subsidiary is preparing for commercial launch within 60-90 days to generate initial revenue in the enterprise AI market, while its lead PTSD therapeutic candidate SPC-15 advances through regulatory milestones including completion of a drug-device robustness study and preparation for an FDA Type C meeting. The company recently raised capital through a private placement to support these initiatives.

  

• GlobeNewswire Inc. 14 jul

  Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

  Silo Pharma announced that its subsidiary QwikAgents has been accepted into Advanced Micro Devices' AMD AI Developer Program. The acceptance provides access to AMD Developer Cloud credits, AI development tools, and technical resources to support QwikAgents' next-generation AI agent platform designed for individuals, developers, small businesses, and enterprises.